Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence Article Swipe
Abdullah Ashraf Hamad
,
Basma Ehab Amer
,
Yousef Hawas
,
Manar Alaa Mabrouk
,
Mostafa Meshref
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1007/s10072-023-07259-w
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1007/s10072-023-07259-w
Objectives Masitinib, originally developed as a tyrosine kinase inhibitor for cancer treatment, has shown potential neuroprotective effects in various neurological disorders by modulating key pathways implicated in neurodegeneration. This scoping review aimed to summarize the current evidence of masitinib’s neuroprotective activities from preclinical to clinical studies. Methods This scoping review was conducted following the guidelines described by Arksey and O’Malley and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The inclusion criteria covered all original studies reporting on the neuroprotective effects of masitinib, including clinical studies, animal studies, and in vitro studies. Results A total of 16 studies met the inclusion criteria and were included in the review. These comprised five randomized controlled trials (RCTs), one post-hoc analysis study, one case report, and nine animal studies. The RCTs focused on Alzheimer’s disease (two studies), multiple sclerosis (two studies), and amyotrophic lateral sclerosis (one study). Across all included studies, masitinib consistently demonstrated neuroprotective properties. However, the majority of RCTs reported concerns regarding the safety profile of masitinib. Preclinical studies revealed the neuroprotective mechanisms of masitinib, which include inhibition of certain kinases interfering with cell proliferation and survival, reduction of neuroinflammation, and exhibition of antioxidant activity. Conclusion The current evidence suggests a promising therapeutic benefit of masitinib in neurodegenerative diseases. However, further research is necessary to validate and expand upon these findings, particularly regarding the precise mechanisms through which masitinib exerts its therapeutic effects. Future studies should also focus on addressing the safety concerns associated with masitinib use.
Related Topics
Concepts
Metadata
- Type
- review
- Language
- en
- Landing Page
- https://doi.org/10.1007/s10072-023-07259-w
- https://link.springer.com/content/pdf/10.1007/s10072-023-07259-w.pdf
- OA Status
- hybrid
- Cited By
- 10
- References
- 55
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4389860991
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4389860991Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1007/s10072-023-07259-wDigital Object Identifier
- Title
-
Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidenceWork title
- Type
-
reviewOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-12-18Full publication date if available
- Authors
-
Abdullah Ashraf Hamad, Basma Ehab Amer, Yousef Hawas, Manar Alaa Mabrouk, Mostafa MeshrefList of authors in order
- Landing page
-
https://doi.org/10.1007/s10072-023-07259-wPublisher landing page
- PDF URL
-
https://link.springer.com/content/pdf/10.1007/s10072-023-07259-w.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
hybridOpen access status per OpenAlex
- OA URL
-
https://link.springer.com/content/pdf/10.1007/s10072-023-07259-w.pdfDirect OA link when available
- Concepts
-
Medicine, Neuroprotection, Oncology, Clinical trial, Amyotrophic lateral sclerosis, Randomized controlled trial, Pharmacology, Internal medicine, DiseaseTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
10Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 8, 2024: 2Per-year citation counts (last 5 years)
- References (count)
-
55Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4389860991 |
|---|---|
| doi | https://doi.org/10.1007/s10072-023-07259-w |
| ids.doi | https://doi.org/10.1007/s10072-023-07259-w |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/38105307 |
| ids.openalex | https://openalex.org/W4389860991 |
| fwci | 1.85670408 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000818 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Animals |
| mesh[1].qualifier_ui | Q000627 |
| mesh[1].descriptor_ui | D018696 |
| mesh[1].is_major_topic | True |
| mesh[1].qualifier_name | therapeutic use |
| mesh[1].descriptor_name | Neuroprotective Agents |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D010880 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Piperidines |
| mesh[3].qualifier_ui | Q000627 |
| mesh[3].descriptor_ui | D011725 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | therapeutic use |
| mesh[3].descriptor_name | Pyridines |
| mesh[4].qualifier_ui | Q000627 |
| mesh[4].descriptor_ui | D001549 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | therapeutic use |
| mesh[4].descriptor_name | Benzamides |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D013844 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | Thiazoles |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D006801 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Humans |
| mesh[7].qualifier_ui | Q000494 |
| mesh[7].descriptor_ui | D018696 |
| mesh[7].is_major_topic | True |
| mesh[7].qualifier_name | pharmacology |
| mesh[7].descriptor_name | Neuroprotective Agents |
| mesh[8].qualifier_ui | Q000627 |
| mesh[8].descriptor_ui | D018696 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | therapeutic use |
| mesh[8].descriptor_name | Neuroprotective Agents |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D000818 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Animals |
| mesh[10].qualifier_ui | Q000494 |
| mesh[10].descriptor_ui | D001549 |
| mesh[10].is_major_topic | True |
| mesh[10].qualifier_name | pharmacology |
| mesh[10].descriptor_name | Benzamides |
| mesh[11].qualifier_ui | Q000627 |
| mesh[11].descriptor_ui | D001549 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | therapeutic use |
| mesh[11].descriptor_name | Benzamides |
| mesh[12].qualifier_ui | Q000494 |
| mesh[12].descriptor_ui | D013844 |
| mesh[12].is_major_topic | True |
| mesh[12].qualifier_name | pharmacology |
| mesh[12].descriptor_name | Thiazoles |
| mesh[13].qualifier_ui | Q000627 |
| mesh[13].descriptor_ui | D013844 |
| mesh[13].is_major_topic | True |
| mesh[13].qualifier_name | therapeutic use |
| mesh[13].descriptor_name | Thiazoles |
| mesh[14].qualifier_ui | Q000494 |
| mesh[14].descriptor_ui | D010880 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | pharmacology |
| mesh[14].descriptor_name | Piperidines |
| mesh[15].qualifier_ui | Q000627 |
| mesh[15].descriptor_ui | D010880 |
| mesh[15].is_major_topic | True |
| mesh[15].qualifier_name | therapeutic use |
| mesh[15].descriptor_name | Piperidines |
| mesh[16].qualifier_ui | Q000494 |
| mesh[16].descriptor_ui | D011725 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | pharmacology |
| mesh[16].descriptor_name | Pyridines |
| mesh[17].qualifier_ui | Q000627 |
| mesh[17].descriptor_ui | D011725 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | therapeutic use |
| mesh[17].descriptor_name | Pyridines |
| mesh[18].qualifier_ui | Q000494 |
| mesh[18].descriptor_ui | D047428 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | pharmacology |
| mesh[18].descriptor_name | Protein Kinase Inhibitors |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D006801 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Humans |
| mesh[20].qualifier_ui | Q000494 |
| mesh[20].descriptor_ui | D018696 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | pharmacology |
| mesh[20].descriptor_name | Neuroprotective Agents |
| mesh[21].qualifier_ui | Q000627 |
| mesh[21].descriptor_ui | D018696 |
| mesh[21].is_major_topic | True |
| mesh[21].qualifier_name | therapeutic use |
| mesh[21].descriptor_name | Neuroprotective Agents |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D000818 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Animals |
| mesh[23].qualifier_ui | Q000494 |
| mesh[23].descriptor_ui | D001549 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | pharmacology |
| mesh[23].descriptor_name | Benzamides |
| mesh[24].qualifier_ui | Q000627 |
| mesh[24].descriptor_ui | D001549 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | therapeutic use |
| mesh[24].descriptor_name | Benzamides |
| mesh[25].qualifier_ui | Q000494 |
| mesh[25].descriptor_ui | D013844 |
| mesh[25].is_major_topic | True |
| mesh[25].qualifier_name | pharmacology |
| mesh[25].descriptor_name | Thiazoles |
| mesh[26].qualifier_ui | Q000627 |
| mesh[26].descriptor_ui | D013844 |
| mesh[26].is_major_topic | True |
| mesh[26].qualifier_name | therapeutic use |
| mesh[26].descriptor_name | Thiazoles |
| mesh[27].qualifier_ui | Q000494 |
| mesh[27].descriptor_ui | D010880 |
| mesh[27].is_major_topic | True |
| mesh[27].qualifier_name | pharmacology |
| mesh[27].descriptor_name | Piperidines |
| mesh[28].qualifier_ui | Q000627 |
| mesh[28].descriptor_ui | D010880 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | therapeutic use |
| mesh[28].descriptor_name | Piperidines |
| mesh[29].qualifier_ui | Q000494 |
| mesh[29].descriptor_ui | D011725 |
| mesh[29].is_major_topic | True |
| mesh[29].qualifier_name | pharmacology |
| mesh[29].descriptor_name | Pyridines |
| mesh[30].qualifier_ui | Q000627 |
| mesh[30].descriptor_ui | D011725 |
| mesh[30].is_major_topic | True |
| mesh[30].qualifier_name | therapeutic use |
| mesh[30].descriptor_name | Pyridines |
| mesh[31].qualifier_ui | Q000494 |
| mesh[31].descriptor_ui | D047428 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | pharmacology |
| mesh[31].descriptor_name | Protein Kinase Inhibitors |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D000818 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Animals |
| mesh[33].qualifier_ui | Q000627 |
| mesh[33].descriptor_ui | D018696 |
| mesh[33].is_major_topic | True |
| mesh[33].qualifier_name | therapeutic use |
| mesh[33].descriptor_name | Neuroprotective Agents |
| mesh[34].qualifier_ui | |
| mesh[34].descriptor_ui | D010880 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | |
| mesh[34].descriptor_name | Piperidines |
| mesh[35].qualifier_ui | Q000627 |
| mesh[35].descriptor_ui | D011725 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | therapeutic use |
| mesh[35].descriptor_name | Pyridines |
| mesh[36].qualifier_ui | Q000627 |
| mesh[36].descriptor_ui | D001549 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | therapeutic use |
| mesh[36].descriptor_name | Benzamides |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D013844 |
| mesh[37].is_major_topic | True |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | Thiazoles |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D000818 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | Animals |
| mesh[39].qualifier_ui | Q000627 |
| mesh[39].descriptor_ui | D018696 |
| mesh[39].is_major_topic | True |
| mesh[39].qualifier_name | therapeutic use |
| mesh[39].descriptor_name | Neuroprotective Agents |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D010880 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Piperidines |
| mesh[41].qualifier_ui | Q000627 |
| mesh[41].descriptor_ui | D011725 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | therapeutic use |
| mesh[41].descriptor_name | Pyridines |
| mesh[42].qualifier_ui | Q000627 |
| mesh[42].descriptor_ui | D001549 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | therapeutic use |
| mesh[42].descriptor_name | Benzamides |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D013844 |
| mesh[43].is_major_topic | True |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Thiazoles |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D006801 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Humans |
| mesh[45].qualifier_ui | Q000494 |
| mesh[45].descriptor_ui | D018696 |
| mesh[45].is_major_topic | True |
| mesh[45].qualifier_name | pharmacology |
| mesh[45].descriptor_name | Neuroprotective Agents |
| mesh[46].qualifier_ui | Q000627 |
| mesh[46].descriptor_ui | D018696 |
| mesh[46].is_major_topic | True |
| mesh[46].qualifier_name | therapeutic use |
| mesh[46].descriptor_name | Neuroprotective Agents |
| mesh[47].qualifier_ui | |
| mesh[47].descriptor_ui | D000818 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | |
| mesh[47].descriptor_name | Animals |
| mesh[48].qualifier_ui | Q000494 |
| mesh[48].descriptor_ui | D001549 |
| mesh[48].is_major_topic | True |
| mesh[48].qualifier_name | pharmacology |
| mesh[48].descriptor_name | Benzamides |
| mesh[49].qualifier_ui | Q000627 |
| mesh[49].descriptor_ui | D001549 |
| mesh[49].is_major_topic | True |
| mesh[49].qualifier_name | therapeutic use |
| mesh[49].descriptor_name | Benzamides |
| type | review |
| title | Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence |
| biblio.issue | 5 |
| biblio.volume | 45 |
| biblio.last_page | 1873 |
| biblio.first_page | 1861 |
| topics[0].id | https://openalex.org/T11533 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.9972000122070312 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1312 |
| topics[0].subfield.display_name | Molecular Biology |
| topics[0].display_name | Melanoma and MAPK Pathways |
| topics[1].id | https://openalex.org/T13265 |
| topics[1].field.id | https://openalex.org/fields/16 |
| topics[1].field.display_name | Chemistry |
| topics[1].score | 0.9962000250816345 |
| topics[1].domain.id | https://openalex.org/domains/3 |
| topics[1].domain.display_name | Physical Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1605 |
| topics[1].subfield.display_name | Organic Chemistry |
| topics[1].display_name | Synthesis of Tetrazole Derivatives |
| topics[2].id | https://openalex.org/T12023 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9940000176429749 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2736 |
| topics[2].subfield.display_name | Pharmacology |
| topics[2].display_name | Cholinesterase and Neurodegenerative Diseases |
| is_xpac | False |
| apc_list.value | 2890 |
| apc_list.currency | EUR |
| apc_list.value_usd | 3690 |
| apc_paid.value | 2890 |
| apc_paid.currency | EUR |
| apc_paid.value_usd | 3690 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.7539865970611572 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C25498285 |
| concepts[1].level | 2 |
| concepts[1].score | 0.7530183792114258 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1981368 |
| concepts[1].display_name | Neuroprotection |
| concepts[2].id | https://openalex.org/C143998085 |
| concepts[2].level | 1 |
| concepts[2].score | 0.532067060470581 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[2].display_name | Oncology |
| concepts[3].id | https://openalex.org/C535046627 |
| concepts[3].level | 2 |
| concepts[3].score | 0.4747600853443146 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q30612 |
| concepts[3].display_name | Clinical trial |
| concepts[4].id | https://openalex.org/C2780596555 |
| concepts[4].level | 3 |
| concepts[4].score | 0.47246289253234863 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q206901 |
| concepts[4].display_name | Amyotrophic lateral sclerosis |
| concepts[5].id | https://openalex.org/C168563851 |
| concepts[5].level | 2 |
| concepts[5].score | 0.43563398718833923 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q1436668 |
| concepts[5].display_name | Randomized controlled trial |
| concepts[6].id | https://openalex.org/C98274493 |
| concepts[6].level | 1 |
| concepts[6].score | 0.4037284851074219 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q128406 |
| concepts[6].display_name | Pharmacology |
| concepts[7].id | https://openalex.org/C126322002 |
| concepts[7].level | 1 |
| concepts[7].score | 0.3671550750732422 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[7].display_name | Internal medicine |
| concepts[8].id | https://openalex.org/C2779134260 |
| concepts[8].level | 2 |
| concepts[8].score | 0.21335619688034058 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[8].display_name | Disease |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.7539865970611572 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/neuroprotection |
| keywords[1].score | 0.7530183792114258 |
| keywords[1].display_name | Neuroprotection |
| keywords[2].id | https://openalex.org/keywords/oncology |
| keywords[2].score | 0.532067060470581 |
| keywords[2].display_name | Oncology |
| keywords[3].id | https://openalex.org/keywords/clinical-trial |
| keywords[3].score | 0.4747600853443146 |
| keywords[3].display_name | Clinical trial |
| keywords[4].id | https://openalex.org/keywords/amyotrophic-lateral-sclerosis |
| keywords[4].score | 0.47246289253234863 |
| keywords[4].display_name | Amyotrophic lateral sclerosis |
| keywords[5].id | https://openalex.org/keywords/randomized-controlled-trial |
| keywords[5].score | 0.43563398718833923 |
| keywords[5].display_name | Randomized controlled trial |
| keywords[6].id | https://openalex.org/keywords/pharmacology |
| keywords[6].score | 0.4037284851074219 |
| keywords[6].display_name | Pharmacology |
| keywords[7].id | https://openalex.org/keywords/internal-medicine |
| keywords[7].score | 0.3671550750732422 |
| keywords[7].display_name | Internal medicine |
| keywords[8].id | https://openalex.org/keywords/disease |
| keywords[8].score | 0.21335619688034058 |
| keywords[8].display_name | Disease |
| language | en |
| locations[0].id | doi:10.1007/s10072-023-07259-w |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S75480959 |
| locations[0].source.issn | 1590-1874, 1590-3478 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 1590-1874 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Neurological Sciences |
| locations[0].source.host_organization | https://openalex.org/P4310319900 |
| locations[0].source.host_organization_name | Springer Science+Business Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310319900 |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://link.springer.com/content/pdf/10.1007/s10072-023-07259-w.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Neurological Sciences |
| locations[0].landing_page_url | https://doi.org/10.1007/s10072-023-07259-w |
| locations[1].id | pmid:38105307 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/38105307 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:11021265 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Neurol Sci |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/11021265 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5088394031 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3849-0995 |
| authorships[0].author.display_name | Abdullah Ashraf Hamad |
| authorships[0].countries | EG |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I63601056 |
| authorships[0].affiliations[0].raw_affiliation_string | Faculty of Medicine, Menoufia University, Menoufia, Egypt |
| authorships[0].institutions[0].id | https://openalex.org/I63601056 |
| authorships[0].institutions[0].ror | https://ror.org/05sjrb944 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I63601056 |
| authorships[0].institutions[0].country_code | EG |
| authorships[0].institutions[0].display_name | Menoufia University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Abdullah Ashraf Hamad |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Faculty of Medicine, Menoufia University, Menoufia, Egypt |
| authorships[1].author.id | https://openalex.org/A5079932036 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-7787-5508 |
| authorships[1].author.display_name | Basma Ehab Amer |
| authorships[1].countries | EG |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I207547235 |
| authorships[1].affiliations[0].raw_affiliation_string | Faculty of Medicine, Benha University, Benha, Egypt |
| authorships[1].institutions[0].id | https://openalex.org/I207547235 |
| authorships[1].institutions[0].ror | https://ror.org/03tn5ee41 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I207547235 |
| authorships[1].institutions[0].country_code | EG |
| authorships[1].institutions[0].display_name | Benha University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Basma Ehab Amer |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Faculty of Medicine, Benha University, Benha, Egypt |
| authorships[2].author.id | https://openalex.org/A5061645361 |
| authorships[2].author.orcid | https://orcid.org/0000-0003-0361-4609 |
| authorships[2].author.display_name | Yousef Hawas |
| authorships[2].countries | EG |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I21376657 |
| authorships[2].affiliations[0].raw_affiliation_string | Faculty of Medicine, Tanta University, Tanta, Egypt |
| authorships[2].institutions[0].id | https://openalex.org/I21376657 |
| authorships[2].institutions[0].ror | https://ror.org/016jp5b92 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I21376657 |
| authorships[2].institutions[0].country_code | EG |
| authorships[2].institutions[0].display_name | Tanta University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Yousef Hawas |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Faculty of Medicine, Tanta University, Tanta, Egypt |
| authorships[3].author.id | https://openalex.org/A5101284704 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Manar Alaa Mabrouk |
| authorships[3].countries | EG |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I66513531 |
| authorships[3].affiliations[0].raw_affiliation_string | Faculty of Medicine, Fayoum University, Fayoum, Egypt |
| authorships[3].institutions[0].id | https://openalex.org/I66513531 |
| authorships[3].institutions[0].ror | https://ror.org/023gzwx10 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I66513531 |
| authorships[3].institutions[0].country_code | EG |
| authorships[3].institutions[0].display_name | Fayoum University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Manar Alaa Mabrouk |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Faculty of Medicine, Fayoum University, Fayoum, Egypt |
| authorships[4].author.id | https://openalex.org/A5074219534 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-0692-6309 |
| authorships[4].author.display_name | Mostafa Meshref |
| authorships[4].countries | EG |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I184834183 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Neurology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt |
| authorships[4].institutions[0].id | https://openalex.org/I184834183 |
| authorships[4].institutions[0].ror | https://ror.org/05fnp1145 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I184834183 |
| authorships[4].institutions[0].country_code | EG |
| authorships[4].institutions[0].display_name | Al-Azhar University |
| authorships[4].author_position | last |
| authorships[4].raw_author_name | Mostafa Meshref |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Neurology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://link.springer.com/content/pdf/10.1007/s10072-023-07259-w.pdf |
| open_access.oa_status | hybrid |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11533 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.9972000122070312 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1312 |
| primary_topic.subfield.display_name | Molecular Biology |
| primary_topic.display_name | Melanoma and MAPK Pathways |
| related_works | https://openalex.org/W2070831599, https://openalex.org/W4206749202, https://openalex.org/W2048256717, https://openalex.org/W2393752460, https://openalex.org/W4292226083, https://openalex.org/W2938751847, https://openalex.org/W4387118726, https://openalex.org/W2077655479, https://openalex.org/W4228996594, https://openalex.org/W2059706093 |
| cited_by_count | 10 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 8 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 2 |
| locations_count | 3 |
| best_oa_location.id | doi:10.1007/s10072-023-07259-w |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S75480959 |
| best_oa_location.source.issn | 1590-1874, 1590-3478 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 1590-1874 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Neurological Sciences |
| best_oa_location.source.host_organization | https://openalex.org/P4310319900 |
| best_oa_location.source.host_organization_name | Springer Science+Business Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310319900 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://link.springer.com/content/pdf/10.1007/s10072-023-07259-w.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Neurological Sciences |
| best_oa_location.landing_page_url | https://doi.org/10.1007/s10072-023-07259-w |
| primary_location.id | doi:10.1007/s10072-023-07259-w |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S75480959 |
| primary_location.source.issn | 1590-1874, 1590-3478 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 1590-1874 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Neurological Sciences |
| primary_location.source.host_organization | https://openalex.org/P4310319900 |
| primary_location.source.host_organization_name | Springer Science+Business Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310319900 |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://link.springer.com/content/pdf/10.1007/s10072-023-07259-w.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Neurological Sciences |
| primary_location.landing_page_url | https://doi.org/10.1007/s10072-023-07259-w |
| publication_date | 2023-12-18 |
| publication_year | 2023 |
| referenced_works | https://openalex.org/W3036652104, https://openalex.org/W2511577826, https://openalex.org/W2102711224, https://openalex.org/W2792952740, https://openalex.org/W4211041983, https://openalex.org/W2495402373, https://openalex.org/W1965411311, https://openalex.org/W2046199264, https://openalex.org/W2954372606, https://openalex.org/W4322488265, https://openalex.org/W3038700455, https://openalex.org/W2058756735, https://openalex.org/W2156098321, https://openalex.org/W2075950485, https://openalex.org/W2891378911, https://openalex.org/W4383863845, https://openalex.org/W2970684805, https://openalex.org/W2101083347, https://openalex.org/W3035234097, https://openalex.org/W1980735023, https://openalex.org/W4212964378, https://openalex.org/W3183535210, https://openalex.org/W2398585811, https://openalex.org/W3203783860, https://openalex.org/W2473397587, https://openalex.org/W2766795446, https://openalex.org/W2895388736, https://openalex.org/W2994699925, https://openalex.org/W3081290650, https://openalex.org/W2024882552, https://openalex.org/W3112997587, https://openalex.org/W2118084349, https://openalex.org/W2106986615, https://openalex.org/W2024324841, https://openalex.org/W1906986388, https://openalex.org/W2119155057, https://openalex.org/W2117867043, https://openalex.org/W2027585107, https://openalex.org/W2900596992, https://openalex.org/W2358666620, https://openalex.org/W2789900283, https://openalex.org/W1986611577, https://openalex.org/W2046170972, https://openalex.org/W3107395714, https://openalex.org/W4206090457, https://openalex.org/W3211761706, https://openalex.org/W2943261811, https://openalex.org/W4281569188, https://openalex.org/W410379109, https://openalex.org/W3194662903, https://openalex.org/W4319869999, https://openalex.org/W4256513592, https://openalex.org/W4225409722, https://openalex.org/W4206965632, https://openalex.org/W4221070974 |
| referenced_works_count | 55 |
| abstract_inverted_index.A | 96 |
| abstract_inverted_index.a | 6, 202 |
| abstract_inverted_index.16 | 99 |
| abstract_inverted_index.as | 5 |
| abstract_inverted_index.by | 22, 57 |
| abstract_inverted_index.in | 18, 27, 92, 108, 208 |
| abstract_inverted_index.is | 214 |
| abstract_inverted_index.of | 38, 84, 98, 159, 167, 175, 180, 190, 194, 206 |
| abstract_inverted_index.on | 80, 132, 240 |
| abstract_inverted_index.to | 33, 44, 216 |
| abstract_inverted_index.The | 72, 129, 198 |
| abstract_inverted_index.all | 76, 148 |
| abstract_inverted_index.and | 59, 61, 69, 91, 105, 125, 141, 187, 192, 218 |
| abstract_inverted_index.for | 10, 66 |
| abstract_inverted_index.has | 13 |
| abstract_inverted_index.its | 232 |
| abstract_inverted_index.key | 24 |
| abstract_inverted_index.met | 101 |
| abstract_inverted_index.one | 118, 122 |
| abstract_inverted_index.the | 35, 54, 62, 81, 102, 109, 157, 164, 172, 225, 242 |
| abstract_inverted_index.was | 51 |
| abstract_inverted_index.(one | 145 |
| abstract_inverted_index.(two | 135, 139 |
| abstract_inverted_index.RCTs | 130, 160 |
| abstract_inverted_index.This | 29, 48 |
| abstract_inverted_index.also | 238 |
| abstract_inverted_index.case | 123 |
| abstract_inverted_index.cell | 185 |
| abstract_inverted_index.five | 113 |
| abstract_inverted_index.from | 42 |
| abstract_inverted_index.nine | 126 |
| abstract_inverted_index.upon | 220 |
| abstract_inverted_index.use. | 248 |
| abstract_inverted_index.were | 106 |
| abstract_inverted_index.with | 184, 246 |
| abstract_inverted_index.Items | 65 |
| abstract_inverted_index.These | 111 |
| abstract_inverted_index.aimed | 32 |
| abstract_inverted_index.focus | 239 |
| abstract_inverted_index.shown | 14 |
| abstract_inverted_index.these | 221 |
| abstract_inverted_index.total | 97 |
| abstract_inverted_index.vitro | 93 |
| abstract_inverted_index.which | 177, 229 |
| abstract_inverted_index.Across | 147 |
| abstract_inverted_index.Arksey | 58 |
| abstract_inverted_index.Future | 235 |
| abstract_inverted_index.animal | 89, 127 |
| abstract_inverted_index.cancer | 11 |
| abstract_inverted_index.exerts | 231 |
| abstract_inverted_index.expand | 219 |
| abstract_inverted_index.kinase | 8 |
| abstract_inverted_index.review | 31, 50 |
| abstract_inverted_index.safety | 165, 243 |
| abstract_inverted_index.should | 237 |
| abstract_inverted_index.study, | 121 |
| abstract_inverted_index.trials | 116 |
| abstract_inverted_index.(RCTs), | 117 |
| abstract_inverted_index.Methods | 47 |
| abstract_inverted_index.Results | 95 |
| abstract_inverted_index.Reviews | 68 |
| abstract_inverted_index.benefit | 205 |
| abstract_inverted_index.certain | 181 |
| abstract_inverted_index.covered | 75 |
| abstract_inverted_index.current | 36, 199 |
| abstract_inverted_index.disease | 134 |
| abstract_inverted_index.effects | 17, 83 |
| abstract_inverted_index.focused | 131 |
| abstract_inverted_index.further | 212 |
| abstract_inverted_index.include | 178 |
| abstract_inverted_index.kinases | 182 |
| abstract_inverted_index.lateral | 143 |
| abstract_inverted_index.precise | 226 |
| abstract_inverted_index.profile | 166 |
| abstract_inverted_index.report, | 124 |
| abstract_inverted_index.review. | 110 |
| abstract_inverted_index.scoping | 30, 49 |
| abstract_inverted_index.studies | 78, 100, 170, 236 |
| abstract_inverted_index.study). | 146 |
| abstract_inverted_index.through | 228 |
| abstract_inverted_index.various | 19 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.However, | 156, 211 |
| abstract_inverted_index.analysis | 120 |
| abstract_inverted_index.clinical | 45, 87 |
| abstract_inverted_index.concerns | 162, 244 |
| abstract_inverted_index.criteria | 74, 104 |
| abstract_inverted_index.effects. | 234 |
| abstract_inverted_index.evidence | 37, 200 |
| abstract_inverted_index.included | 107, 149 |
| abstract_inverted_index.majority | 158 |
| abstract_inverted_index.multiple | 137 |
| abstract_inverted_index.original | 77 |
| abstract_inverted_index.pathways | 25 |
| abstract_inverted_index.post-hoc | 119 |
| abstract_inverted_index.reported | 161 |
| abstract_inverted_index.research | 213 |
| abstract_inverted_index.revealed | 171 |
| abstract_inverted_index.studies, | 88, 90, 150 |
| abstract_inverted_index.studies. | 46, 94, 128 |
| abstract_inverted_index.suggests | 201 |
| abstract_inverted_index.tyrosine | 7 |
| abstract_inverted_index.validate | 217 |
| abstract_inverted_index.Preferred | 63 |
| abstract_inverted_index.Reporting | 64 |
| abstract_inverted_index.activity. | 196 |
| abstract_inverted_index.comprised | 112 |
| abstract_inverted_index.conducted | 52 |
| abstract_inverted_index.described | 56 |
| abstract_inverted_index.developed | 4 |
| abstract_inverted_index.diseases. | 210 |
| abstract_inverted_index.disorders | 21 |
| abstract_inverted_index.findings, | 222 |
| abstract_inverted_index.following | 53 |
| abstract_inverted_index.including | 86 |
| abstract_inverted_index.inclusion | 73, 103 |
| abstract_inverted_index.inhibitor | 9 |
| abstract_inverted_index.masitinib | 151, 207, 230, 247 |
| abstract_inverted_index.necessary | 215 |
| abstract_inverted_index.potential | 15 |
| abstract_inverted_index.promising | 203 |
| abstract_inverted_index.reduction | 189 |
| abstract_inverted_index.regarding | 163, 224 |
| abstract_inverted_index.reporting | 79 |
| abstract_inverted_index.sclerosis | 138, 144 |
| abstract_inverted_index.studies), | 136, 140 |
| abstract_inverted_index.summarize | 34 |
| abstract_inverted_index.survival, | 188 |
| abstract_inverted_index.Conclusion | 197 |
| abstract_inverted_index.Masitinib, | 2 |
| abstract_inverted_index.Objectives | 1 |
| abstract_inverted_index.O’Malley | 60 |
| abstract_inverted_index.Systematic | 67 |
| abstract_inverted_index.activities | 41 |
| abstract_inverted_index.addressing | 241 |
| abstract_inverted_index.associated | 245 |
| abstract_inverted_index.controlled | 115 |
| abstract_inverted_index.exhibition | 193 |
| abstract_inverted_index.guidelines | 55 |
| abstract_inverted_index.implicated | 26 |
| abstract_inverted_index.inhibition | 179 |
| abstract_inverted_index.masitinib, | 85, 176 |
| abstract_inverted_index.masitinib. | 168 |
| abstract_inverted_index.mechanisms | 174, 227 |
| abstract_inverted_index.modulating | 23 |
| abstract_inverted_index.originally | 3 |
| abstract_inverted_index.randomized | 114 |
| abstract_inverted_index.treatment, | 12 |
| abstract_inverted_index.Preclinical | 169 |
| abstract_inverted_index.amyotrophic | 142 |
| abstract_inverted_index.antioxidant | 195 |
| abstract_inverted_index.guidelines. | 71 |
| abstract_inverted_index.interfering | 183 |
| abstract_inverted_index.preclinical | 43 |
| abstract_inverted_index.properties. | 155 |
| abstract_inverted_index.therapeutic | 204, 233 |
| abstract_inverted_index.consistently | 152 |
| abstract_inverted_index.demonstrated | 153 |
| abstract_inverted_index.neurological | 20 |
| abstract_inverted_index.particularly | 223 |
| abstract_inverted_index.Alzheimer’s | 133 |
| abstract_inverted_index.Meta-Analyses | 70 |
| abstract_inverted_index.masitinib’s | 39 |
| abstract_inverted_index.proliferation | 186 |
| abstract_inverted_index.neuroprotective | 16, 40, 82, 154, 173 |
| abstract_inverted_index.neurodegenerative | 209 |
| abstract_inverted_index.neurodegeneration. | 28 |
| abstract_inverted_index.neuroinflammation, | 191 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 94 |
| corresponding_author_ids | https://openalex.org/A5088394031 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 5 |
| corresponding_institution_ids | https://openalex.org/I63601056 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.7799999713897705 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.8601807 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |